Stabilized amorphous glibenclamide nanoparticles by high-gravity technique

Materials Chemistry and Physics

Volumn 130, Issue 1-2, 2011, Pages 361-366

  Yu, Lei ^a   Li, Caixia ^a   Le, Yuan ^a   Chen, Jian Feng ^a   Zou, Haikui ^a  

^a BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

Amorphous materials; Nanostructures; Precipitation; Recrystallisation

Indexed keywords

ANTI-SOLVENTS; CRYSTALLINE FORM; DISSOLUTION RATES; DISSOLUTION TESTS; FOURIER TRANSFORM INFRARED; GLIBENCLAMIDE; HIGH-GRAVITY; MEAN SIZE; NARROW DISTRIBUTION; OPERATING VARIABLES; PHYSICAL STABILITY; RECRYSTALLISATION;

DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; FOURIER TRANSFORMS; NANOPARTICLES; PRECIPITATION (CHEMICAL); SCANNING ELECTRON MICROSCOPY; X RAY DIFFRACTION;

AMORPHOUS MATERIALS;

EID: 80052604859     PISSN: 02540584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matchemphys.2011.06.049     Document Type: Article

References (32)

1. S. Mutalik, and N. Udupa Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations J. Pharm. Sci. 93 6 2004 1577 1594 (Pubitemid 38725029)
2. H.J. Arnqvist, B.E. Karlberg, and A. Melander Pharmacokinetics and effects of glibenclamide in two formulations, HB 419 and HB 420, in type 2 diabetes Ann. Clin. Res. 37 1983 21 25 (Pubitemid 14124718)
3. J.B. Chalk, M. Patterson, M.T. Smith, and M.J. Eadie Correlation between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide Eur. J. Clin. Pharmacol. 31 1986 177 182 (Pubitemid 17014586)
4. M. Perrut, J. Jung, and F. Leboeuf Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes. Part I: micronization of neat particles Int. J. Pharm. 288 2005 3 10 (Pubitemid 39656449)
5. W. Rupp, M. Badian, W. Heptner, and V. Malerczyk Bioavailability and in vitro liberation of glibenclamide from a new dosage form Biopharm. Pharmacokinet., Eur. Congr. 2nd. 1 1984 413 420
6. S.L. Raghavan, A. Trividic, A.F. Davis, and J. Hadgraft Crystallization of hydrocortisone acetate: influence of polymers Int. J. Pharm. 212 2003 213 221
7. J. Singh Effect of sodium lauryl sulfate and Tween 80 on the therapeutic efficacy of glibenclamide tablet formulations in terms of BSL lowering in rabbits and diabetic human volunteers Drug Dev. Ind. Pharm. 12 1986 851 866 (Pubitemid 16120824)
8. J.A. Ganley, J. McEven, R.T. Calvert, and C.J. Barker The effect of in vivo dispension and gastric emptying on glibenclamide absorption from a novel, rapidly dissolving capsule formulation J. Pharm. Pharmacol. 36 1984 734 739 (Pubitemid 14021953)
9. A. Mitrevej, N. Sinchaipanid, V. Junyaprasert, and L. Warintornuwat Effect of grinding of cyclodextrin and glibenclamide on tablet properties Drug Dev. Ind. Pharm. 22 1996 1237 1241 (Pubitemid 26413041)
10. C. Goddeeris, T. Willems, and G.V.D. Mooter Formulation of fast disintegrating tablets of ternary solid dispersions consisting of TPGS 1000 and HPMC 2910 or PVPVA 64 to improve the dissolution of the anti-HIV drug UC 871 Eur. J. Pharm. Sci. 34 2008 293 302
11. B.C. Hancock, and M. Parks What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17 2000 397 404 (Pubitemid 30395293)
12. B.C. Hancock, and G. Zografi Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 86 1997 1 12
13. M.A. Hassan, N.M. Najib, and M.S. Suleiman Characterization of glibenclamide glassy state Int. J. Pharm. 67 1991 131 137
14. Z. Wojnarowska, K. Grzybowska, K. Adrjanowicz, and K. Kaminski Study of the amorphous glibenclamide drug: analysis of the molecular dynamics of quenched and cryomilled material Mol. Pharm. 7 2010 1692 1707
15. N. Rasenack, H. Steckel, and B.W. Müller Preparation of microcrystals by in situ micronization Powder Technol. 143-144 2004 291 296 (Pubitemid 39091949)
16. J. Hecq, M. Deleers, D. Franara, H. Vranckx, P. Boulanger, S.L. Lamer, and K. Amighi Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enchancement of ucb-35440-3, a highly dosed poorly water-soluble weak base Eur. J. Pharm. Biopharm. 64 2006 360 368 (Pubitemid 44585201)
17. D. Wei, H.R. Dave, and R. Pfeffer Mixing and characterization of nanosized powders: an assessment of different techniques J. Nanopart. Res. 42 2002 21 41 (Pubitemid 135713399)
18. J.F. Chen, Y.H. Wang, F. Guo, X.M. Wang, and C. Zheng Synthesis of nanoparticles with novel technology: highgravity reactive precipitation Ind. Eng. Chem. Res. 39 2000 948 954 (Pubitemid 30210636)
19. J.F. Chen, M.Y. Zhou, L. Shao, Y.H. Wang, J. Yun, N.Y.K. Chew, and H.K. Chan Feasibility of preparing nanodrugs by high gravity reactive precipitation Int. J. Pharm. 269 2004 267 274 (Pubitemid 38032839)
20. J.Y. Zhang, Z.G. Shen, J. Zhong, T.T. Hu, J.F. Chen, Z.Q. Ma, and J. Yun Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants Int. J. Pharm. 323 2006 153 160 (Pubitemid 44397363)
21. T.J. Young, S.M. Mawson, K.P. Johnston, I.B. Henriksen, G.W. Pace, and A.K. Mishra Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs Biotechnol. Prog. 16 2000 402 407 (Pubitemid 30369011)
22. M. Sarkari, J. Brown Chen, X.S. Swinnea, R.O. Williams III, and K.P. Johnston Enhanced drug dissolution using evaporative precipitation into aqueous solution Int. J. Pharm. 243 1-2 2002 17 31
23. T.L. Rogers, I.B. Gillespie, J.E. Hitt, K.L. Fransen, C.A. Crowl, C.J. Tucker, G.B. Kupperblatt, J.N. Becker, D.L. Wilson, and C. Todd Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs Pharm. Res. 21 2004 2048 2057 (Pubitemid 40941225)
24. M.E. Matteucci, M.A. Hotze, K.P. Johnston, and R.O. Williams III Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization Langmuir 22 2006 8951 8959 (Pubitemid 44626160)
25. N. EI-Gendy, and C. Berkland Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration Pharm. Res. 26 2009 1752 1763
26. M.B. Chougule, B.K. Padhi, K.A. Jinturkar, and A. Misra Development of dry powder inhalers Recent Pat. Drug Deliv. Formul. 1 2007 11 21
27. H.X. Zhang, J.X. Wanga, Z.B. Zhang, Y. Le, Z.G. Shen, and J.F. Chen Micronization of atorvastatin calcium by antisolvent precipitation process Int. J. Pharm. 374 2009 106 113
28. I. Katzhendlera, R. Azouryb, and M. Friedmana Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets based on hydroxypropyl methylcellulose J. Controll. Release 54 1998 69 85
29. J.C. Dinunzio, D.A. Miller, W. Yang, G.W. Mcginity, and R.O. Williams Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole Mol. Pharm. 5 2008 968 980
30. N.P. Praetorius, and T.K. Mandal Engineered nanoparticles in cancer therapy Recent Pat. Drug Deliv. Formul. 1 2007 37 51
31. S. Galindo-Rodriguez, S.E. Allemann, H. Fessi, and E. Doelker Physicochemical parameters associated with nanoparticle formation in the tsaltingout, emulsification-diffusion, and nanoprecipitation methods Pharm. Res. 21 2004 1428 1439 (Pubitemid 39149658)
32. N. Blagden, M. de Matas, P.T. Gavan, and P. York Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates Adv. Drug Deliv. Rev. 59 2007 617 630 (Pubitemid 47285407)